

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-5 (Canceled).

Claim 6 (Currently amended):        Monoclonal antibody ~~according to claim 4~~ produced from the cell line deposited at the American Type Culture Collection (ATCC) under Accession No. PTA-4837 or a clone thereof.

Claims 7-10 (Canceled).

Claim 11 (Withdrawn – Currently amended):        A method for the detection of an epitope of an inactivated FIV-encoded glycoprotein in a sample which comprises: contacting said sample with a monoclonal antibody produced from the cell line deposited at the American Type Culture Collection (ATCC) under Accession No. PTA-4837 or a clone thereof ~~specific for an epitope of an inactivated FIV-encoded glycoprotein~~, wherein the monoclonal antibody specifically reacts with or recognizes the epitope of the inactivated FIV or inactivated FIV glycoprotein but does not react with or recognize live FIV or live FIV glycoprotein, to form a complex; and detecting said complex.

Claims 12-14 (Canceled)

Claim 15 (Withdrawn – Currently amended):        A method for the preparation of a monoclonal ~~antibodies~~ antibody produced from the cell line deposited at the American Type Culture Collection (ATCC) under Accession No. PTA-4837 or a clone thereof ~~specific for an epitope of an inactivated FIV-encoded glycoprotein~~ which comprises immunizing a suitable

host with a partially purified, inactivated FIV, screening the host for high FIV-specific antibody response, fusing splenocytes from said host with a suitable myeloma cell line to generate hybridoma cells, screening said hybridoma cells for specific reactivity with inactivated FIV, and then selecting a stable clone, growing said stable clone and harvesting the desired monoclonal antibodies, wherein the monoclonal antibody specifically reacts with or recognizes the epitope of the inactivated FIV or inactivated FIV glycoprotein but does not react with or recognize live FIV or live FIV glycoprotein.

Claim 16 (Withdrawn): The method according to claim 15 wherein the inactivated FIV is FIV-Shiz or FIV-Petaluma.

Claim 17 (Withdrawn): The method according to claim 15 wherein said inactivated FIV is FIV-Shiz.

Claim 18 (Withdrawn – Currently amended): The method according to ~~any of claims~~ claim 15 wherein said FIV has been inactivated by treatment with formalin.

Claim 19 (Currently amended): A hybridoma cell line deposited at the American Type Culture Collection under Accession No. PTA-4837 or a clone thereof, suitable for obtaining of monoclonal antibodies specific for an epitope of an inactivated FIV-encoded glycoprotein, ~~wherein the monoclonal antibodies specifically react with or recognize the epitope of the inactivated FIV or inactivated FIV glycoprotein but does not react with or recognize live FIV or live FIV glycoprotein~~, prepared by immunizing a suitable host with a partially purified, inactivated FIV, screening the host for high FIV-specific antibody response, ~~and~~ fusing splenocytes from said host with a suitable myeloma cell line, and screening hybridomas for specific reactivity with inactivated FIV wherein there is no reaction with or recognition of live FIV.

Application No. 10/648,667  
Amendment dated July 26, 2007  
Reply to Office action of May 30, 2007

Claim 20 (Currently amended): The cell line of claim 19 which is suitable for obtaining a monoclonal antibody specific for an epitope of an inactivated FIV-encoded glycoprotein selected from gp 95 and gp 130.

Claim 21 (Canceled).

Claim 22 (Original): The cell line deposited at the American Type Culture Collection under Accession No. PTA-4837.